[ad_1]
- Sinopharmwhich makes two of the vaccines that are distributed through China’s emergency use authorization program, applied for market approval last month. However, the company has yet to release the results of the Phase 3 trial.
- Sinovac Biotech has made a vaccine it calls CoronaVac, which has also been widely distributed in China outside of clinical trials, even as trials continue in countries like Brazil.
- CanSino Biologics Y Anhui Zhifei Longcom Biopharmaceutical they also have vaccines in phase 3 trials.
- Shenzhen Kangtai Organic Products, one of China’s largest vaccine manufacturers, and one with a scandal-ridden past, will be “the exclusive manufacturer in mainland China of the vaccine made by the British-Swedish pharmaceutical giant AstraZeneca,” reports the New York Times. It is also developing its own vaccine, although it is not as advanced in testing as the other four companies.
Mass distribution of Chinese vaccines is beginning, even as governments await more data from clinical trials and official approval of the products.
- “Provincial governments throughout China, ”including Jiangsu, Sichuan and Anhui, have recently said they have purchased supplies of domestic vaccines or are considering doing so, the Associated Press reports.
- Indonesia has received 1.2 million doses of the Sinovac Biotech vaccine, and a plan to distribute the doses is expected to be “completed in two weeks,” reports the Straits Times. A second shipment of “1.8 million doses of the Sinovac vaccine will arrive in January.”
- Brazil It has also received “more than a million doses” of the Sinovac Biotech vaccine, which will be distributed until it is approved, says the Wall Street Journal.
- Turkey has “pre-ordered 50 million doses” of Chinese vaccines, according to the WSJ.
- Chile has also reached a supply agreement with Sinovac Biotech, according to Reuters, and speaks to the Philippines they are underway.
Sinovac has raised $ 515 million from Sino Biopharmaceutical, one of China’s largest pharmaceutical companies, to increase its vaccine production, according to Caixin.
- The company is “now analyzing interim data from phase 3 trials in Brazil, after which it will send the data to the Chinese drug regulator.”
- According to the biomedical center of Brazil’s Butantan Institute, Sinovac is expected to “publish the efficacy results of its vaccine trials before December 15,” according to Reuters.
